Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novel Biologics Will Get Suffixes (Or At Least One Did)

Executive Summary

US FDA's approval of Ultragenyx's Mepsevii (vestronidase alfa-vjbk) marks first novel biologic with a suffix, but 10 months after release of the naming guidance how – and even how widely – FDA will implement the policy remains uncertain.

Advertisement

Related Content

First Three Novel Biologic Suffixes Came Courtesy Of US FDA, Not Sponsors
Canada Wants Views On Three Options For Naming Of Biologic Drugs
Novartis Stockpiling Priority Review Vouchers
Novartis Stockpiling Priority Review Vouchers
Keeping Track: A Massive Week Of Agency Approvals
Biologics Naming: US FDA Ponders How To Put New System In Place, While WHO Puts Hold On Pilot Study
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
Novel Biologics In US Might Not Start Getting Suffixes Until August
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121976

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel